What drives company decisions on new medicine launches and UK investment?
In this piece, David Watson, ABPI Executive Director of Patient Access, discusses the findings of ABPI's 2025 Medicines Impact and Investment Survey, which aims to supplement existing data to…
Read the full articleYou might also wanna read
NHS Fast-tracks Life-changing Medicines in Landmark UK-US Access Overhaul
A new series of NHS pilot schemes could give patients access to innovative medicines months earlier while supporting investment in the UK's
Aligning Investments in Therapeutic Development with Therapeutic Need Closing the Gap
Final Book Now Available The United States is a global leader in biomedical research, generating therapeutic breakthroughs that advance the
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Targeted therapies meet AI-driven discovery as these biotech innovators reveal sharply contrasting financials, risk factors, and industry pa
UK Life Sciences Must Move From Innovation Pilots to National Adoption
The UK is not short of innovation. The challenge is building the national systems, funding routes and procurement models needed to turn prom
New Zealand minister pushes Pharmac to use AI for faster medicine funding decisions
The minister responsible for drug-buying agency Pharmac is doubling down on his call for it to make greater use of artificial intelligence,
rnz.co.nz·14d ago
China creates new regulatory pathway to accelerate access to advanced biomedical therapies
The country’s new regulatory pathway promises to accelerate access to advanced therapies for Chinese patients, but may change the licensing
biopharmadive.com·26d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.